Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,982
archived clinical trials in
Endocrine

Insulin Resistance Intervention After Stroke Trial
Insulin Resistance Intervention After Stroke (IRIS) Trial
Status: Enrolling
Updated:  1/6/2016
Flinders Medical Centre
mi
from 98109
Bedford Park,
Insulin Resistance Intervention After Stroke Trial
Insulin Resistance Intervention After Stroke (IRIS) Trial
Status: Enrolling
Updated: 1/6/2016
Flinders Medical Centre
mi
from 98109
Bedford Park,
Click here to add this to my saved trials
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated:  1/6/2016
Boehringer Ingelheim Investigational Site
2079
mi
from 98109
Birmingham, AL
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated: 1/6/2016
Boehringer Ingelheim Investigational Site
2079
mi
from 98109
Birmingham, AL
Click here to add this to my saved trials
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated:  1/6/2016
1199.14.1181 Boehringer Ingelheim Investigational Site
982
mi
from 98109
Long Beach, CA
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated: 1/6/2016
1199.14.1181 Boehringer Ingelheim Investigational Site
982
mi
from 98109
Long Beach, CA
Click here to add this to my saved trials
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated:  1/6/2016
1218.74.01144 Boehringer Ingelheim Investigational Site
952
mi
from 98109
North Hollywood, CA
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated: 1/6/2016
1218.74.01144 Boehringer Ingelheim Investigational Site
952
mi
from 98109
North Hollywood, CA
Click here to add this to my saved trials
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated:  1/6/2016
Boehringer Ingelheim Investigational Site
1020
mi
from 98109
Denver, CO
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated: 1/6/2016
Boehringer Ingelheim Investigational Site
1020
mi
from 98109
Denver, CO
Click here to add this to my saved trials
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated:  1/6/2016
Boehringer Ingelheim Investigational Site
2732
mi
from 98109
Miami, FL
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated: 1/6/2016
Boehringer Ingelheim Investigational Site
2732
mi
from 98109
Miami, FL
Click here to add this to my saved trials
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated:  1/6/2016
205.452.01153 Boehringer Ingelheim Investigational Site
1865
mi
from 98109
Evansville, IN
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated: 1/6/2016
205.452.01153 Boehringer Ingelheim Investigational Site
1865
mi
from 98109
Evansville, IN
Click here to add this to my saved trials
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated:  1/6/2016
1218.64.10004 Boehringer Ingelheim Investigational Site
1884
mi
from 98109
Flint, MI
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated: 1/6/2016
1218.64.10004 Boehringer Ingelheim Investigational Site
1884
mi
from 98109
Flint, MI
Click here to add this to my saved trials
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated:  1/6/2016
1245.25.10008 Boehringer Ingelheim Investigational Site
1984
mi
from 98109
Jackson, MS
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated: 1/6/2016
1245.25.10008 Boehringer Ingelheim Investigational Site
1984
mi
from 98109
Jackson, MS
Click here to add this to my saved trials
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated:  1/6/2016
1218.75.038 Boehringer Ingelheim Investigational Site
2310
mi
from 98109
Asheboro, NC
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated: 1/6/2016
1218.75.038 Boehringer Ingelheim Investigational Site
2310
mi
from 98109
Asheboro, NC
Click here to add this to my saved trials
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated:  1/6/2016
Boehringer Ingelheim Investigational Site
2281
mi
from 98109
Charlotte, NC
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated: 1/6/2016
Boehringer Ingelheim Investigational Site
2281
mi
from 98109
Charlotte, NC
Click here to add this to my saved trials
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated:  1/6/2016
1160.129.32833 Boehringer Ingelheim Investigational Site
1194
mi
from 98109
Fargo, ND
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated: 1/6/2016
1160.129.32833 Boehringer Ingelheim Investigational Site
1194
mi
from 98109
Fargo, ND
Click here to add this to my saved trials
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated:  1/6/2016
Boehringer Ingelheim Investigational Site
2008
mi
from 98109
Columbus, OH
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated: 1/6/2016
Boehringer Ingelheim Investigational Site
2008
mi
from 98109
Columbus, OH
Click here to add this to my saved trials
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated:  1/6/2016
Boehringer Ingelheim Investigational Site
1523
mi
from 98109
Oklahoma City, OK
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated: 1/6/2016
Boehringer Ingelheim Investigational Site
1523
mi
from 98109
Oklahoma City, OK
Click here to add this to my saved trials
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated:  1/6/2016
1160.129.32082 Boehringer Ingelheim Investigational Site
2110
mi
from 98109
Knoxville, TN
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated: 1/6/2016
1160.129.32082 Boehringer Ingelheim Investigational Site
2110
mi
from 98109
Knoxville, TN
Click here to add this to my saved trials
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated:  1/6/2016
Boehringer Ingelheim Investigational Site
1890
mi
from 98109
Houston, TX
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated: 1/6/2016
Boehringer Ingelheim Investigational Site
1890
mi
from 98109
Houston, TX
Click here to add this to my saved trials
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated:  1/6/2016
1218.89.11004 Boehringer Ingelheim Investigational Site
562
mi
from 98109
Edmonton,
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Status: Enrolling
Updated: 1/6/2016
1218.89.11004 Boehringer Ingelheim Investigational Site
562
mi
from 98109
Edmonton,
Click here to add this to my saved trials
Impact of Muscle Insulin Resistance on the Pathogenesis of Non Alcoholic Steatohepatitis
Predictive Value of Inflammation and Fibrosis in Skeletal Muscle for Liver Histopathology in Patients With Non Alcoholic Fatty Liver Disease: Impact of Muscle Insulin Resistance on the Pathogenesis of Non Alcoholic Steatohepatitis
Status: Enrolling
Updated:  1/7/2016
Mayo Clinic
1104
mi
from 98109
Phoenix, AZ
Impact of Muscle Insulin Resistance on the Pathogenesis of Non Alcoholic Steatohepatitis
Predictive Value of Inflammation and Fibrosis in Skeletal Muscle for Liver Histopathology in Patients With Non Alcoholic Fatty Liver Disease: Impact of Muscle Insulin Resistance on the Pathogenesis of Non Alcoholic Steatohepatitis
Status: Enrolling
Updated: 1/7/2016
Mayo Clinic
1104
mi
from 98109
Phoenix, AZ
Click here to add this to my saved trials
The Influence of Vitamin D on Atypical Antipsychotic-induced Weight Gain
The Role of Vitamin D and Quetiapine-induced Weight Gain
Status: Enrolling
Updated:  1/7/2016
Alegent Creighton Clinic - Psychiatric Associates (Dodge Street)
1367
mi
from 98109
Omaha, NE
The Influence of Vitamin D on Atypical Antipsychotic-induced Weight Gain
The Role of Vitamin D and Quetiapine-induced Weight Gain
Status: Enrolling
Updated: 1/7/2016
Alegent Creighton Clinic - Psychiatric Associates (Dodge Street)
1367
mi
from 98109
Omaha, NE
Click here to add this to my saved trials
How Quickly Can the Effects of Excessive Caloric Intake on Insulin Resistance be Reversed?
How Quickly Can the Effects of Excessive Caloric Intake on Insulin Resistance be Reversed?
Status: Enrolling
Updated:  1/7/2016
Temple University Hospital
2373
mi
from 98109
Philadelphia, PA
How Quickly Can the Effects of Excessive Caloric Intake on Insulin Resistance be Reversed?
How Quickly Can the Effects of Excessive Caloric Intake on Insulin Resistance be Reversed?
Status: Enrolling
Updated: 1/7/2016
Temple University Hospital
2373
mi
from 98109
Philadelphia, PA
Click here to add this to my saved trials
Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With Lipodystrophy
Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With Lipodystrophy
Status: Enrolling
Updated:  1/8/2016
University of Michigan
1903
mi
from 98109
Ann Arbor, MI
Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With Lipodystrophy
Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With Lipodystrophy
Status: Enrolling
Updated: 1/8/2016
University of Michigan
1903
mi
from 98109
Ann Arbor, MI
Click here to add this to my saved trials
Management of Mineral and Bone Disease in Hemodialysis-Calcitriol vs. Paricalcitol
A Randomized, Prospective, Cross-Over Study of Calcitriol vs. Paricalcitol in the Treatment of Mineral and Bone Disease in Hemodialysis Patients
Status: Enrolling
Updated:  1/11/2016
Winthrop University Hospital
2417
mi
from 98109
Mineola, NY
Management of Mineral and Bone Disease in Hemodialysis-Calcitriol vs. Paricalcitol
A Randomized, Prospective, Cross-Over Study of Calcitriol vs. Paricalcitol in the Treatment of Mineral and Bone Disease in Hemodialysis Patients
Status: Enrolling
Updated: 1/11/2016
Winthrop University Hospital
2417
mi
from 98109
Mineola, NY
Click here to add this to my saved trials
Genomic Research in Sarcoidosis
Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis (GRADS) - Sarcoidosis Protocol
Status: Enrolling
Updated:  1/11/2016
Arizona Health Sciences Center
1219
mi
from 98109
Tucson, AZ
Genomic Research in Sarcoidosis
Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis (GRADS) - Sarcoidosis Protocol
Status: Enrolling
Updated: 1/11/2016
Arizona Health Sciences Center
1219
mi
from 98109
Tucson, AZ
Click here to add this to my saved trials
Genomic Research in Sarcoidosis
Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis (GRADS) - Sarcoidosis Protocol
Status: Enrolling
Updated:  1/11/2016
National Jewish Health
1022
mi
from 98109
Denver, CO
Genomic Research in Sarcoidosis
Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis (GRADS) - Sarcoidosis Protocol
Status: Enrolling
Updated: 1/11/2016
National Jewish Health
1022
mi
from 98109
Denver, CO
Click here to add this to my saved trials
Genomic Research in Sarcoidosis
Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis (GRADS) - Sarcoidosis Protocol
Status: Enrolling
Updated:  1/11/2016
Yale University
2432
mi
from 98109
New Haven, CT
Genomic Research in Sarcoidosis
Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis (GRADS) - Sarcoidosis Protocol
Status: Enrolling
Updated: 1/11/2016
Yale University
2432
mi
from 98109
New Haven, CT
Click here to add this to my saved trials
Genomic Research in Sarcoidosis
Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis (GRADS) - Sarcoidosis Protocol
Status: Enrolling
Updated:  1/11/2016
Johns Hopkins University
2326
mi
from 98109
Baltimore, MD
Genomic Research in Sarcoidosis
Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis (GRADS) - Sarcoidosis Protocol
Status: Enrolling
Updated: 1/11/2016
Johns Hopkins University
2326
mi
from 98109
Baltimore, MD
Click here to add this to my saved trials
Genomic Research in Sarcoidosis
Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis (GRADS) - Sarcoidosis Protocol
Status: Enrolling
Updated:  1/11/2016
Univ of Pennsylvania
2371
mi
from 98109
Philadelphia, PA
Genomic Research in Sarcoidosis
Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis (GRADS) - Sarcoidosis Protocol
Status: Enrolling
Updated: 1/11/2016
Univ of Pennsylvania
2371
mi
from 98109
Philadelphia, PA
Click here to add this to my saved trials
Genomic Research in Sarcoidosis
Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis (GRADS) - Sarcoidosis Protocol
Status: Enrolling
Updated:  1/11/2016
University of Pittsburgh
2134
mi
from 98109
Pittsburgh, PA
Genomic Research in Sarcoidosis
Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis (GRADS) - Sarcoidosis Protocol
Status: Enrolling
Updated: 1/11/2016
University of Pittsburgh
2134
mi
from 98109
Pittsburgh, PA
Click here to add this to my saved trials
Genomic Research in Sarcoidosis
Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis (GRADS) - Sarcoidosis Protocol
Status: Enrolling
Updated:  1/11/2016
Medical University of South Caolina
2422
mi
from 98109
Charleston, SC
Genomic Research in Sarcoidosis
Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis (GRADS) - Sarcoidosis Protocol
Status: Enrolling
Updated: 1/11/2016
Medical University of South Caolina
2422
mi
from 98109
Charleston, SC
Click here to add this to my saved trials
Genomic Research in Sarcoidosis
Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis (GRADS) - Sarcoidosis Protocol
Status: Enrolling
Updated:  1/11/2016
Vanderbilt University
1970
mi
from 98109
Nashville, TN
Genomic Research in Sarcoidosis
Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis (GRADS) - Sarcoidosis Protocol
Status: Enrolling
Updated: 1/11/2016
Vanderbilt University
1970
mi
from 98109
Nashville, TN
Click here to add this to my saved trials
Genomic Research in Sarcoidosis
Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis (GRADS) - Sarcoidosis Protocol
Status: Enrolling
Updated:  1/11/2016
University of California at San Francisco
682
mi
from 98109
San Francisco, CA
Genomic Research in Sarcoidosis
Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis (GRADS) - Sarcoidosis Protocol
Status: Enrolling
Updated: 1/11/2016
University of California at San Francisco
682
mi
from 98109
San Francisco, CA
Click here to add this to my saved trials
Efficacy, Pharmacokinetics and Safety of Testosterone
A Phase 2 Open-label, Sequential Dose Escalation Study to Evaluate the Efficacy, Pharmacokinetics and Safety of Three Volumes of Topical Testosterone in Hypogonadal Males
Status: Enrolling
Updated:  1/13/2016
Accumed Research Associates
2418
mi
from 98109
Garden City, NY
Efficacy, Pharmacokinetics and Safety of Testosterone
A Phase 2 Open-label, Sequential Dose Escalation Study to Evaluate the Efficacy, Pharmacokinetics and Safety of Three Volumes of Topical Testosterone in Hypogonadal Males
Status: Enrolling
Updated: 1/13/2016
Accumed Research Associates
2418
mi
from 98109
Garden City, NY
Click here to add this to my saved trials
Exercise Dose Response for Improving Insulin Sensitivity
Comparing the Effects Exercise Intensity and Energy Expended During a Single Exercise Session on Insulin Sensitivity and Fatty Acid Partitioning Within Skeletal Muscle the Next Day in Obese Adults.
Status: Enrolling
Updated:  1/14/2016
Michigan Clincal Research Unit
1901
mi
from 98109
Ann Arbor, MI
Exercise Dose Response for Improving Insulin Sensitivity
Comparing the Effects Exercise Intensity and Energy Expended During a Single Exercise Session on Insulin Sensitivity and Fatty Acid Partitioning Within Skeletal Muscle the Next Day in Obese Adults.
Status: Enrolling
Updated: 1/14/2016
Michigan Clincal Research Unit
1901
mi
from 98109
Ann Arbor, MI
Click here to add this to my saved trials
CoaguChek XS in Antiphospholipid Antibody Syndrome (APL) Patients
Accuracy of CoaguChek XS in Patients With Antiphospholipid Antibody Syndrome
Status: Enrolling
Updated:  1/19/2016
UF and Shands Health
2453
mi
from 98109
Gainesville, FL
CoaguChek XS in Antiphospholipid Antibody Syndrome (APL) Patients
Accuracy of CoaguChek XS in Patients With Antiphospholipid Antibody Syndrome
Status: Enrolling
Updated: 1/19/2016
UF and Shands Health
2453
mi
from 98109
Gainesville, FL
Click here to add this to my saved trials
How Vitamin D Analogues Affect Endothelial Cells in Patients on Dialysis
Effect of Doxercalciferol on Endothelial Cell Function in End Stage Renal Disease
Status: Enrolling
Updated:  1/20/2016
Duke University Medical Center Dialysis Unit
2338
mi
from 98109
Durham, NC
How Vitamin D Analogues Affect Endothelial Cells in Patients on Dialysis
Effect of Doxercalciferol on Endothelial Cell Function in End Stage Renal Disease
Status: Enrolling
Updated: 1/20/2016
Duke University Medical Center Dialysis Unit
2338
mi
from 98109
Durham, NC
Click here to add this to my saved trials
A Study of Intrathecal Enzyme Therapy for Cognitive Decline in MPS I
A Study of Intrathecal Enzyme Replacement for Cognitive Decline in Mucopolysaccharidosis I
Status: Enrolling
Updated:  1/22/2016
Children's Hospital and Research Center Oakland
677
mi
from 98109
Oakland, CA
A Study of Intrathecal Enzyme Therapy for Cognitive Decline in MPS I
A Study of Intrathecal Enzyme Replacement for Cognitive Decline in Mucopolysaccharidosis I
Status: Enrolling
Updated: 1/22/2016
Children's Hospital and Research Center Oakland
677
mi
from 98109
Oakland, CA
Click here to add this to my saved trials
A Study of Intrathecal Enzyme Therapy for Cognitive Decline in MPS I
A Study of Intrathecal Enzyme Replacement for Cognitive Decline in Mucopolysaccharidosis I
Status: Enrolling
Updated:  1/22/2016
Los Angeles Biomedical Institute at Harbor-UCLA
976
mi
from 98109
Torrance, CA
A Study of Intrathecal Enzyme Therapy for Cognitive Decline in MPS I
A Study of Intrathecal Enzyme Replacement for Cognitive Decline in Mucopolysaccharidosis I
Status: Enrolling
Updated: 1/22/2016
Los Angeles Biomedical Institute at Harbor-UCLA
976
mi
from 98109
Torrance, CA
Click here to add this to my saved trials
A Study of Intrathecal Enzyme Therapy for Cognitive Decline in MPS I
A Study of Intrathecal Enzyme Replacement for Cognitive Decline in Mucopolysaccharidosis I
Status: Enrolling
Updated:  1/22/2016
Univ of Minnesota
1393
mi
from 98109
Minneapolis, MN
A Study of Intrathecal Enzyme Therapy for Cognitive Decline in MPS I
A Study of Intrathecal Enzyme Replacement for Cognitive Decline in Mucopolysaccharidosis I
Status: Enrolling
Updated: 1/22/2016
Univ of Minnesota
1393
mi
from 98109
Minneapolis, MN
Click here to add this to my saved trials
ACTIV- Exercise Intervention in Healthy Young Men
"ACTIV"Validation of a Paradigm for the Evaluation of Compounds That Activate Mitochondrial Biogenesis in Skeletal Muscle
Status: Enrolling
Updated:  1/22/2016
Pennington Biomedical Research Center
2031
mi
from 98109
Baton Rouge, LA
ACTIV- Exercise Intervention in Healthy Young Men
"ACTIV"Validation of a Paradigm for the Evaluation of Compounds That Activate Mitochondrial Biogenesis in Skeletal Muscle
Status: Enrolling
Updated: 1/22/2016
Pennington Biomedical Research Center
2031
mi
from 98109
Baton Rouge, LA
Click here to add this to my saved trials
Diabetic Treatment Adherence
Treatment Adherence With Compliance Prompting Packaging
Status: Enrolling
Updated:  1/25/2016
University of Texas M.D. Anderson Cancer Center
1892
mi
from 98109
Houston, TX
Diabetic Treatment Adherence
Treatment Adherence With Compliance Prompting Packaging
Status: Enrolling
Updated: 1/25/2016
University of Texas M.D. Anderson Cancer Center
1892
mi
from 98109
Houston, TX
Click here to add this to my saved trials
Diabetic Treatment Adherence
Treatment Adherence With Compliance Prompting Packaging
Status: Enrolling
Updated:  1/25/2016
Kelsey-Seybold Clinics
1890
mi
from 98109
Houston, TX
Diabetic Treatment Adherence
Treatment Adherence With Compliance Prompting Packaging
Status: Enrolling
Updated: 1/25/2016
Kelsey-Seybold Clinics
1890
mi
from 98109
Houston, TX
Click here to add this to my saved trials
Effect of EGCG on the Body's Response to Insulin
An Exploratory Study to Evaluate the Ability of Epigallocatechin Gallate to Simultaneously Improve Metabolic and Cardiovascular Actions of Insulin in Healthy and Obese Subjects
Status: Enrolling
Updated:  1/28/2016
University of Maryland
2327
mi
from 98109
Baltimore, MD
Effect of EGCG on the Body's Response to Insulin
An Exploratory Study to Evaluate the Ability of Epigallocatechin Gallate to Simultaneously Improve Metabolic and Cardiovascular Actions of Insulin in Healthy and Obese Subjects
Status: Enrolling
Updated: 1/28/2016
University of Maryland
2327
mi
from 98109
Baltimore, MD
Click here to add this to my saved trials
Reducing Risk of Type 2 Diabetes: Hydroxychloroquine Use in Pre-Diabetes
Mechanisms of Action of Hydroxychloroquine in Reducing Risk of Type 2 Diabetes
Status: Enrolling
Updated:  1/28/2016
University of Pittsburgh, Montefiore Hospital
2132
mi
from 98109
Pittsburgh, PA
Reducing Risk of Type 2 Diabetes: Hydroxychloroquine Use in Pre-Diabetes
Mechanisms of Action of Hydroxychloroquine in Reducing Risk of Type 2 Diabetes
Status: Enrolling
Updated: 1/28/2016
University of Pittsburgh, Montefiore Hospital
2132
mi
from 98109
Pittsburgh, PA
Click here to add this to my saved trials
Effects of Hesperidin on Insulin Sensitivity
An Exploratory Study to Evaluate the Ability of the Citrus Polyphenol Hesperidin to Improve Insulin Sensitivity in Healthy Subjects and to Ameliorate Insulin Resistance in Obese Subjects
Status: Enrolling
Updated:  1/28/2016
University of Maryland
2327
mi
from 98109
Baltimore, MD
Effects of Hesperidin on Insulin Sensitivity
An Exploratory Study to Evaluate the Ability of the Citrus Polyphenol Hesperidin to Improve Insulin Sensitivity in Healthy Subjects and to Ameliorate Insulin Resistance in Obese Subjects
Status: Enrolling
Updated: 1/28/2016
University of Maryland
2327
mi
from 98109
Baltimore, MD
Click here to add this to my saved trials
Metabolic Effects of Short Term Sugarcane Bagasse Supplementation
Metabolic Effects of Short Term Sugarcane Bagasse Supplementation
Status: Enrolling
Updated:  2/1/2016
Pennington Biomedical Research Center
2031
mi
from 98109
Baton Rouge, LA
Metabolic Effects of Short Term Sugarcane Bagasse Supplementation
Metabolic Effects of Short Term Sugarcane Bagasse Supplementation
Status: Enrolling
Updated: 2/1/2016
Pennington Biomedical Research Center
2031
mi
from 98109
Baton Rouge, LA
Click here to add this to my saved trials
Reciprocating Medical Devices - a Study of a New Safety Device
Randomized Controlled Trial of the Reciprocating Procedure Device Versus the Conventional Syringe in Syringe-and-Needle Procedures
Status: Enrolling
Updated:  2/2/2016
University of New Mexico Health Sciences Center
1186
mi
from 98109
Albuquerque, NM
Reciprocating Medical Devices - a Study of a New Safety Device
Randomized Controlled Trial of the Reciprocating Procedure Device Versus the Conventional Syringe in Syringe-and-Needle Procedures
Status: Enrolling
Updated: 2/2/2016
University of New Mexico Health Sciences Center
1186
mi
from 98109
Albuquerque, NM
Click here to add this to my saved trials
FGF-23 (Fibroblast Growth Factor 23) Regulation in Chronic Kidney Disease
Status: Enrolling
Updated:  2/2/2016
UCLA
979
mi
from 98109
Los Angeles, CA
FGF-23 (Fibroblast Growth Factor 23) Regulation in Chronic Kidney Disease
Status: Enrolling
Updated: 2/2/2016
UCLA
979
mi
from 98109
Los Angeles, CA
Click here to add this to my saved trials
Effects of Acipimox on Mitochondrial Function in Obesity
The Effects of Short Term Acipimox Treatment on Skeletal Muscle Phosphocreatine Recovery in Obesity
Status: Enrolling
Updated:  2/2/2016
Massachusetts General Hospital
2485
mi
from 98109
Boston, MA
Effects of Acipimox on Mitochondrial Function in Obesity
The Effects of Short Term Acipimox Treatment on Skeletal Muscle Phosphocreatine Recovery in Obesity
Status: Enrolling
Updated: 2/2/2016
Massachusetts General Hospital
2485
mi
from 98109
Boston, MA
Click here to add this to my saved trials
A Quality Initiative to Improve Glycemic Control in Diabetic and Non-Diabetic Insulin Study
A Quality Initiative to Improve Glycemic Control in Diabetic and Non-Diabetic Patients After Vascular Surgery
Status: Enrolling
Updated:  2/2/2016
Fletcher Allen Health Care
2325
mi
from 98109
Burlington, VT
A Quality Initiative to Improve Glycemic Control in Diabetic and Non-Diabetic Insulin Study
A Quality Initiative to Improve Glycemic Control in Diabetic and Non-Diabetic Patients After Vascular Surgery
Status: Enrolling
Updated: 2/2/2016
Fletcher Allen Health Care
2325
mi
from 98109
Burlington, VT
Click here to add this to my saved trials
Impact of Fluid Milk on Post-meal Glycemia and Insulinemia in Overwt/Obese Adults
Impact of Fluid Milk on Post-meal Glycemia and Insulinemia in Overweight/Obese Adults With Normal or Impaired Glucose Tolerance or Type 2 Diabetes
Status: Enrolling
Updated:  2/4/2016
Purdue University
1811
mi
from 98109
West Lafayette, IN
Impact of Fluid Milk on Post-meal Glycemia and Insulinemia in Overwt/Obese Adults
Impact of Fluid Milk on Post-meal Glycemia and Insulinemia in Overweight/Obese Adults With Normal or Impaired Glucose Tolerance or Type 2 Diabetes
Status: Enrolling
Updated: 2/4/2016
Purdue University
1811
mi
from 98109
West Lafayette, IN
Click here to add this to my saved trials